NASDAQ: RZLT Rezolute, Inc. 10-Q

Rezolute's lead Phase 3 trial fails; FDA review ongoing, workforce cut 40%

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade RZLT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.